These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

557 related articles for article (PubMed ID: 26728598)

  • 21. ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells.
    Holcakova J; Nekulova M; Orzol P; Nenutil R; Podhorec J; Svoboda M; Dvorakova P; Pjechova M; Hernychova L; Vojtesek B; Coates PJ
    Breast Cancer Res Treat; 2017 Jun; 163(3):475-484. PubMed ID: 28349272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
    Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
    Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating the landscape of gene cooperativity with receptor tyrosine kinases in liver tumorigenesis using transposon-mediated mutagenesis.
    Fan Y; Bazai SK; Daian F; Arechederra M; Richelme S; Temiz NA; Yim A; Habermann BH; Dono R; Largaespada DA; Maina F
    J Hepatol; 2019 Mar; 70(3):470-482. PubMed ID: 30529386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A critical role for ras-mediated, epidermal growth factor receptor-dependent angiogenesis in mouse skin carcinogenesis.
    Casanova ML; Larcher F; Casanova B; Murillas R; Fernández-Aceñero MJ; Villanueva C; Martínez-Palacio J; Ullrich A; Conti CJ; Jorcano JL
    Cancer Res; 2002 Jun; 62(12):3402-7. PubMed ID: 12067982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined inhibition of EGFR and c-ABL suppresses the growth of triple-negative breast cancer growth through inhibition of HOTAIR.
    Wang YL; Overstreet AM; Chen MS; Wang J; Zhao HJ; Ho PC; Smith M; Wang SC
    Oncotarget; 2015 May; 6(13):11150-61. PubMed ID: 25883211
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis.
    Zhou X; Coad J; Ducatman B; Agazie YM
    Histopathology; 2008 Oct; 53(4):389-402. PubMed ID: 18643929
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.
    Furcht CM; Buonato JM; Skuli N; Mathew LK; Muñoz Rojas AR; Simon MC; Lazzara MJ
    J Cell Sci; 2014 Aug; 127(Pt 16):3555-67. PubMed ID: 24951116
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
    Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX
    Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells.
    Kuribayashi A; Kataoka K; Kurabayashi T; Miura M
    Endocrinology; 2004 Nov; 145(11):4976-84. PubMed ID: 15271882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comprehensive review of SHP2 and its role in cancer.
    Asmamaw MD; Shi XJ; Zhang LR; Liu HM
    Cell Oncol (Dordr); 2022 Oct; 45(5):729-753. PubMed ID: 36066752
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SHP2 promotes laryngeal cancer growth through the Ras/Raf/Mek/Erk pathway and serves as a prognostic indicator for laryngeal cancer.
    Gu J; Han T; Ma RH; Zhu YL; Jia YN; Du JJ; Chen Y; Jiang XJ; Xie XD; Guo X
    Int J Oncol; 2014 Feb; 44(2):481-90. PubMed ID: 24297342
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SHP2 Drives Adaptive Resistance to ERK Signaling Inhibition in Molecularly Defined Subsets of ERK-Dependent Tumors.
    Ahmed TA; Adamopoulos C; Karoulia Z; Wu X; Sachidanandam R; Aaronson SA; Poulikakos PI
    Cell Rep; 2019 Jan; 26(1):65-78.e5. PubMed ID: 30605687
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Genetic modifiers of EGFR dependence in non-small cell lung cancer.
    Sharifnia T; Rusu V; Piccioni F; Bagul M; Imielinski M; Cherniack AD; Pedamallu CS; Wong B; Wilson FH; Garraway LA; Altshuler D; Golub TR; Root DE; Subramanian A; Meyerson M
    Proc Natl Acad Sci U S A; 2014 Dec; 111(52):18661-6. PubMed ID: 25512530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrow-derived mast cells.
    McPherson VA; Sharma N; Everingham S; Smith J; Zhu HH; Feng GS; Craig AW
    J Immunol; 2009 Oct; 183(8):4940-7. PubMed ID: 19786542
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PI3K inhibition circumvents resistance to SHP2 blockade in metastatic triple-negative breast cancer.
    Amante RJ; Jehanno C; De Silva D; Coissieux MM; Ackerknecht M; Romanet V; Sethi A; Hamelin B; Preca BT; Piscuoglio S; Ng CKY; Mohseni M; Bentires-Alj M
    J Mammary Gland Biol Neoplasia; 2023 Jun; 28(1):13. PubMed ID: 37294349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
    Prahallad A; Heynen GJ; Germano G; Willems SM; Evers B; Vecchione L; Gambino V; Lieftink C; Beijersbergen RL; Di Nicolantonio F; Bardelli A; Bernards R
    Cell Rep; 2015 Sep; 12(12):1978-85. PubMed ID: 26365186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Shp2 negatively regulates growth in cardiomyocytes by controlling focal adhesion kinase/Src and mTOR pathways.
    Marin TM; Clemente CF; Santos AM; Picardi PK; Pascoal VD; Lopes-Cendes I; Saad MJ; Franchini KG
    Circ Res; 2008 Oct; 103(8):813-24. PubMed ID: 18757826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.